233 related articles for article (PubMed ID: 19487287)
1. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
4. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
5. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
6. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis.
Korkolopoulou P; Patsouris E; Konstantinidou AE; Pavlopoulos PM; Kavantzas N; Boviatsis E; Thymara I; Perdiki M; Thomas-Tsagli E; Angelidakis D; Rologis D; Sakkas D
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):267-78. PubMed ID: 15175080
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach.
Takahashi R; Tanaka S; Hiyama T; Ito M; Kitadai Y; Sumii M; Haruma K; Chayama K
Oncol Rep; 2003; 10(4):797-802. PubMed ID: 12792726
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Cheng J; Slavin RE; Gallagher JA; Zhu G; Biehl TR; Swanstrom LL; Hansen PD
J Hepatobiliary Pancreat Surg; 2004; 11(3):164-70. PubMed ID: 15235888
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor expression and angiogenesis in human prostate carcinoma.
Abdulkadir SA; Carvalhal GF; Kaleem Z; Kisiel W; Humphrey PA; Catalona WJ; Milbrandt J
Hum Pathol; 2000 Apr; 31(4):443-7. PubMed ID: 10821491
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
[TBL] [Abstract][Full Text] [Related]
12. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ
In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
Sakai I; Harada K; Hara I; Eto H; Miyake H
BJU Int; 2005 Sep; 96(4):528-32. PubMed ID: 16104904
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis.
Zhong H; Semenza GL; Simons JW; De Marzo AM
Cancer Detect Prev; 2004; 28(2):88-93. PubMed ID: 15068831
[TBL] [Abstract][Full Text] [Related]
16. Independent association of angiogenesis index with outcome in prostate cancer.
Mehta R; Kyshtoobayeva A; Kurosaki T; Small EJ; Kim H; Stroup R; McLaren CE; Li KT; Fruehauf JP
Clin Cancer Res; 2001 Jan; 7(1):81-8. PubMed ID: 11205922
[TBL] [Abstract][Full Text] [Related]
17. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
Yang J; Wu HF; Qian LX; Zhang W; Hua LX; Yu ML; Wang Z; Xu ZQ; Sui YG; Wang XR
Asian J Androl; 2006 Mar; 8(2):169-75. PubMed ID: 16491267
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer.
Ismail AH; Altaweel W; Chevalier S; Kassouf W; Aprikian AG
Can J Urol; 2004 Feb; 11(1):2146-50. PubMed ID: 15003156
[TBL] [Abstract][Full Text] [Related]
19. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy.
Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
Anticancer Res; 2001; 21(6A):4071-6. PubMed ID: 11911294
[TBL] [Abstract][Full Text] [Related]
20. Expression of vascular endothelial growth factor (VEGF) in vulvar squamous cancer and VIN.
Lewy-Trenda I; Wierzchniewska-ławska A; Papierz W
Pol J Pathol; 2005; 56(1):5-8. PubMed ID: 15921007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
